Predictive Multimodal Signatures Associated With Response to Treatment and Prognosis of Patients With Stage IV Non-small Cell Lung Cancer
Running, not enrolling
Conditions studied: Non-small Cell Lung Cancer Metastatic
In brief
Predicting response to therapy and disease progression in stage IV NSCLC patients treated with pembrolizumab monotherapy, chemotherapy-pembrolizumab combination therapy or chemotherapy alone in the first-line setting.
Key facts
- Study ID
- NCT04994795
- Run by
- Sophia Genetics SAS
- People needed
- 4000
- Starts
- 2021-08-21
- Expected to finish
- 2025-02-01
- Last updated by the study team
- 2024-11-21
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Adult ≥18 years old
- Patient diagnosed with Stage IV NSCLC (de novo or earlier stage progression to stage IV)
- Absence of oncogene activating mutations eligible patients to targeted therapy (EGFR, ALK)
- Cohort A: Received first line treatment with pembrolizumab monotherapy
- Cohort B: Received first line treatment with chemotherapy and pembrolizumab combination therapy
- Cohort C: Received first line treatment with chemotherapy doublet
You may not qualify if…
- Prior anti-cancer therapy for actual stage IV NSCLC
- Critical data missing (e.g., PD-L1 status, baseline millimetric imaging, first evaluation millimetric imaging)
- Patients participating in other clinical trials that modify the standard of care
Where it is running
- Holden Comprehensive Cancer Center at University of Iowa Health Care — Iowa City, Iowa, United States
- UMASS Memorial Health — Worcester, Massachusetts, United States
- Mayo Clinic — Rochester, Minnesota, United States
- Roswell Park Comprehensive Cancer Center — Buffalo, New York, United States
- Huntsman Cancer Institute — Salt Lake City, Utah, United States
- Carbone Comprehensive Cancer Center at University of Wisconsin — Madison, Wisconsin, United States
- DASA - Hospital Brasilia — Brasília, Brazil
- DASA - Hospital de Niteroi — Niterói, Brazil
- DASA - Hospital São Lucas — Rio de Janeiro, Brazil
- DASA - Hospital Nove De Julho — São Paulo, Brazil
- AC Camargo — São Paulo, Brazil
- Sunnybrook Health Sciences Centre Toronto — Toronto, Canada
- Avicenne Hospital — Bobigny, France
- CHU Bordeaux — Bordeaux, France
- Ambroise Paré Hospital — Boulogne-Billancourt, France
- Hospices Civils de Lyon — Lyon, France
- CHU de Nantes — Nantes, France
- La Pitié Salpêtrière — Paris, France
- Tenon Hospital — Paris, France
- Foch Hospital — Suresnes, France
- Centre Hospitalier de Toulon — Toulon, France
- University Hospital Leipzig — Leipzig, Germany
- Shaare Zadek Medical Center — Jerusalem, Israel
- Sourasky Medical Center — Tel Aviv, Israel
- University Hospital Of Parma — Parma, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.